Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Ceilleachair AO, Finn C, Deady S, Carsin AE, Sharp L. Have developments in palliative care services impacted on place of death of colorectal cancer patients in Ireland? A population-based study. Irish J Med Sci. 2011 Mar;180(1):91-6. doi: 10.1007/s11845-010-0607-y
Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004
Drummond FJ, Carsin AE, Sharp L, Comber H. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Irish J Med Sci. 2010 Mar;179(1):43-9. doi: 10.1007/s11845-009-0376-7
Espaulella J, Guyer H, Diaz-Escriu F, Mellado-Navas JA, Castells M, Pladevall-Vila M. Nutritional supplementation of elderly hip fracture patients. A randomized, double-blind, placebo-controlled trial. Age Ageing. 2000 Sep;29(5):425-31.